Your browser doesn't support javascript.
loading
Clues of HLAs, metabolic SNPs, and epigenetic factors in T cell-mediated drug hypersensitivity reactions.
Molatefi, Rasol; Talebi, Sedighe; Samei, Azam; Roshanravan, Neda; Manshouri, Shirin; Hashemi, Baran; Ghobadi Dana, Vahid; Mosharkesh, Erfan; Bahar, Mohammad Ali; Khajoei, Sholeh; Seif, Farhad.
Afiliação
  • Molatefi R; Cancer Immunology and Immunotherapy Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.
  • Talebi S; Department of Traditional Medicine, School of Persian Medicine, Shahed University, Tehran, Iran.
  • Samei A; Department of Laboratory Sciences, School of Allied Medical Sciences, Kashan University of Medical Sciences, Kashan, Iran.
  • Roshanravan N; Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Manshouri S; Rajaei Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Hashemi B; Rajaei Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Ghobadi Dana V; Department of Immunology and Allergy, Academic Center for Education, Culture, and Research (ACECR), Tehran, Iran.
  • Mosharkesh E; Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran.
  • Bahar MA; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Khajoei S; Clinical Research Development Center, Imam Khomeini Hospital, Jiroft University of Medical Sciences, Jiroft, Iran.
  • Seif F; Department of Photodynamic Therapy, Medical Laser Research Center, Academic Center for Education, Culture, and Research (ACECR), Tehran, Iran.
Heliyon ; 10(14): e33976, 2024 Jul 30.
Article em En | MEDLINE | ID: mdl-39100437
ABSTRACT
Drug hypersensitivities are common reactions due to immunologic responses. They are of utmost importance because they may generate severe and fatal outcomes. Some drugs may cause Adverse Drug Reactions (ADRs), such as drug hypersensitivity reactions (DHRs), which can occur due to the interaction of intact drugs or their metabolites with Human Leukocyte Antigens (HLAs) and T cell receptors (TCRs). This type develops over a period of 24-72 h after exposure and is classified as type IV of DHRs. Acute generalized exanthematic pustulosis (AGEP), Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) are types of Severe Cutaneous Adverse Reactions (SCARs). In this review, we aim to discuss the types of ADRs, the mechanisms involved in their development, and the role of immunogenetic factors, such as HLAs in type IV DHRs, single-nucleotide polymorphisms (SNPs), and some epigenetic modifications, e.g., DNA/histone methylation in a variety of genes and their promoters which may predispose subjects to DHRs. In conclusion, development of promising novel in vitro or in vivo diagnostic and prognostic markers is essential for identifying susceptible subjects or providing treatment protocols to work up patients with drug allergies as personalized medicine.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article